ArticleJID innovations : skin science from molecules to population health2025
Transcriptomic Analysis Identifies Disease Severity and Therapeutic Response in Psoriasis.
Article in JID innovations : skin science from molecules to population health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormalities in gene expression profiles characterize patients with inflammatory skin diseases, including psoriasis, and changes may reflect the action of specific therapeutic agents. To examine this, gene expression analysis of psoriatic skin was assessed by Gene Set Variation Analysis using informative gene modules, and longitudinal data were analyzed to assess the impact of various treatments. Ridge penalized logistic regression was employed to derive a transcriptomic score. Psoriatic lesional skin exhibited perturbations in gene expression profiles at baseline, with enrichment of signatures for neutrophils, keratinocytes, IFN, IL-12 complex, IL-1 cytokines, TNF, and T helper 17. Treatment with a variety of agents reduced lesional gene expression abnormalities to those in nonlesional skin. Specific gene expression abnormalities at baseline identified clinical responders to each treatment. Changes in gene expression over time were less pronounced in nonlesional skin and lesional skin in clinical nonresponders. The combined transcriptomic scores showed significant positive correlations with PASI scores in clinical responders over time. Overall, gene expression abnormalities characterize the severity of psoriatic skin lesions, can be used to predict responsiveness to individual treatments, and revert toward those of nonlesional skin with effective therapy. Therefore, gene expression analysis can be useful to support management of patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.